Aktienanalyse wird geladen …
MRK · NYSE · Pharmaceuticals · USA
148,00 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 65,01 Mrd. | 18,25 Mrd. | 7,28 $ | 2,51 Mrd. | 5,5 Mio · 0,2 % | 39,5 Mio · 1,6 % | 74,8 % | 28,1 % | 4,93 $ | 0,33 $ | 3,28 $ |
| 2024 | 64,17 Mrd. | 17,12 Mrd. | 6,74 $ | 2,54 Mrd. | 5,1 Mio · 0,2 % | 11,1 Mio · 0,4 % | 76,3 % | 26,7 % | 7,12 $ | 0,30 $ | 3,12 $ |
| 2023 | 60,12 Mrd. | 365 Mio. | 0,14 $ | 2,55 Mrd. | 4,4 Mio · 0,2 % | — | 73,2 % | 0,6 % | 3,59 $ | 0,25 $ | 2,96 $ |
| 2022 | 59,28 Mrd. | 14,52 Mrd. | 5,71 $ | 2,54 Mrd. | 3,7 Mio · 0,1 % | — | 70,6 % | 24,5 % | 5,79 $ | 0,21 $ | 2,80 $ |
| 2021 | 48,7 Mrd. | 13,05 Mrd. | 5,14 $ | 2,54 Mrd. | 3,2 Mio · 0,1 % | 6,2 Mio · 0,2 % | 72 % | 26,8 % | 3,42 $ | 0,19 $ | 2,64 $ |
| 2020 | 41,52 Mrd. | 7,07 Mrd. | 2,78 $ | 2,54 Mrd. | 3 Mio · 0,1 % | 42 Mio · 1,7 % | 67,2 % | 17 % | 2,29 $ | 0,17 $ | 2,48 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q2 2026 | 16,61 Mrd. | -1,34 Mrd. | -0,54 $ | 2,47 Mrd. | -8 % | 1,81 $ |
| Q1 2026 | 16,29 Mrd. | -4,24 Mrd. | -1,72 $ | 2,47 Mrd. | -26 % | 1,18 $ |
| Q4 2025 | 16,4 Mrd. | 2,96 Mrd. | 1,18 $ | 2,49 Mrd. | 18,1 % | 0,73 $ |
| Q3 2025 | 17,28 Mrd. | 5,79 Mrd. | 2,32 $ | 2,5 Mrd. | 33,5 % | 2,74 $ |
| Q2 2025 | 15,81 Mrd. | 4,43 Mrd. | 1,76 $ | 2,51 Mrd. | 28 % | 1,01 $ |
| Q1 2025 | 15,53 Mrd. | 5,08 Mrd. | 2,01 $ | 2,53 Mrd. | 32,7 % | 0,46 $ |
| Q4 2024 | 15,62 Mrd. | 3,74 Mrd. | 1,49 $ | — | 24 % | 1,00 $ |
| Q3 2024 | 16,66 Mrd. | 3,16 Mrd. | 1,24 $ | 2,54 Mrd. | 19 % | 3,35 $ |
Merck & Co., Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing medicines, vaccines, biologic therapies, and animal health products. The company’s pharmaceutical business serves areas such as oncology, immunology, infectious diseases, cardiometabolic conditions, neuroscience, and hospital care, while its vaccine portfolio supports preventive care across pediatric, adolescent, and adult populations. Merck & Co., Inc. also operates an animal health segment that provides veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals. Its products are distributed through healthcare providers, wholesalers, pharmacies, hospitals, veterinarians, and government channels, giving the company a broad role across human and animal health markets. Headquartered in Rahway, New Jersey, Merck & Co., Inc. is recognized for its research-intensive model and its presence in essential therapeutic and preventive care categories worldwide.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest MRK und jede andere Aktie unbegrenzt.